

Principles of Clinical Pharmacology
NIH, April 23, 2009

Role of FDA

in

Guiding Drug Development

Carl Peck, MD

UCSF Center for Drug Development Science
Washington DC and San Francisco

Department of Biopharmaceutical Sciences
School of Pharmacy,
University of California San Francisco

UCSF

University of California
San Francisco



Acknowledgements & Affiliations

- **Contributors to ideas presented today**
 - All of my colleagues in FDA

- **Disclosures**
 - CDDS (<http://cdds.ucsf.edu>)
 - NDA Partners LLC (www.ndapartners.com)
 - SimCyp SAB



Why FDA ?

What comprises FDA guidance ?

How does FDA guide drug development?

When does FDA get involved ?

What's new at FDA ?



Why FDA ?

- **FD&C Act: history and its supporters**
 - **resulted from public safety events or public health challenges**
 - ~ 1902/6, 1938, 1962, 1972, 1984, 1987, 1997, **2004-2007**
 - **a uniquely American phenomenon**
 - **Investment in FDA**
 - **Media and Politicization**
- **Evolution of Drug Regulation (R. Temple)**

SAFETY → *EFFECTIVENESS* → *INDIVIDUALIZATION*
..... → *PERSONALIZATION* → *SAFETY*

What comprises FDA guidance ?

■ Standards

- ❑ chemistry and manufacturing controls (CMC)
- ❑ preclinical animal toxicology requirements
- ❑ ethics of human clinical trials
- ❑ documentary requirements for INDs, & NDAs
- ❑ Electronic records (21 CFR part 11)

■ Clinical trials

- ❑ safety
- ❑ effectiveness
- ❑ trial design

How does FDA guide drug development ?

- **Written guidances**
 - Regulations, guidelines (incl. ICH), guidances
 - Literature publications
 - Regulatory letters
 - (Statute, Congressional Reports)
- **Face-to-face & telephonic meetings**
 - Pre-IND, EoP2, EoP2a, EoP2, pre-NDA, others as-needed
- **FDA Advisory Committee meetings**
- **Podium presentations**

Website - www.fda.gov

How many guidances and are they binding ?

■ GUIDANCES

- ❑ > 500 guidances (final/draft, FDA/ICH)

■ Guidance documents:

- ❑ Cannot legally bind FDA or the public
- ❑ Recognizes value of consistency & predictability
- ❑ Because companies want assurance
- ❑ So staff will apply statute & regulations consistently

www.fda.gov/cder/guidance.htm

Clinical Pharmacology Guidances

- Drug Metabolism/Drug Interaction Studies in the Drug Development Process: Studies In Vitro (97); In Vivo (99)
- Pharmacokinetics in Patients w/renal & impaired hepatic function: study design, data analysis, dosing/labeling
- Pediatric Pharmacokinetic Studies for Drugs Biological
- Population Pharmacokinetics (99)
- Exposure-Response (02)
- Exploratory IND Studies (April 2005)



Contains Nonbinding Recommendations

Guidance for Industry, Investigators, and Reviewers

Exploratory IND Studies

*Office of Training and Communication
Division of Drug Information, HFD-240
Center for Drug Evaluation and Research
Food and Drug Administration
5600 Fishers Lane
Rockville, MD 20857
(Tel) 301-827-4573
<http://www.fda.gov/cder/guidance/index.htm>*

**U.S. Department of Health and Human Services
Food and Drug Administration
Center for Drug Evaluation and Research (CDER)**

**January 2006
Pharmacology/Toxicology**



University of California
San Francisco

UCSF-CDDS 2009



Clinical/Medical Guidances

- **Study and Evaluation of Gender Differences in the Clinical Evaluation of Drugs (93)**
- **Study of Drugs ... used in the Elderly (89)**
- **Guidance for Institutional Review Boards, Clinical Investigators, and Sponsors: Exception from Informed Consent Requirements for Emergency Research**
- **Providing Clinical Evidence of Effectiveness for Human Drug and Biological Products (98)**

Statutory Guidance: *FDA Modernization Act of 1997 - “FDAMA”*

- Sec. 111. *Pediatric* studies of drugs
 - PK bridging studies
- Sec. 115a. Clinical investigations
 - support of one adequate and well-controlled clinical investigation by “confirmatory evidence” comprising PK or PK/PD

Pediatric Labeling Regulations

“FDA may approve a drug for pediatric use based on ... studies in adults, with other information supporting pediatric use.... additional information supporting pediatric use must ordinarily include data on the pharmacokinetics of the drug in the pediatric populationOther information, such as data on pharmacodynamic studies.....”

(21 CFR 201.56)

FDAMA, Sec. 115a

Clinical investigations

“If the Secretary determines, based on relevant science, that data from one adequate and well-controlled clinical investigation and confirmatory evidence are sufficient to establish effectiveness, the Secretary may consider such data and evidence to constitute substantial evidence..”

FDAMA, Sec. 115a CONGRESSIONAL COMMITTEE REPORTS

- **“confirmatory evidence” = “scientifically sound data from any investigation in the NDA that provides substantiation as to the safety and effectiveness of the new drug”**
- **confirmatory evidence = “consisting of earlier clinical trials, pharmacokinetic data, or other appropriate scientific studies”**

1 House Commerce Committee, 10/7/97, and Committee of Conference on Disagreeing votes of the two Houses, 11/9/97

New Formulations and Doses of Already Approved Drugs

- Where ***blood levels ... are not very different***, it may be possible to conclude ... is effective on the basis of **pharmacokinetic data alone**.
- Even ***if blood levels are quite different***, if there is **a well-understood relationship between blood concentration and response**, ..., it may be possible to conclude ... is effective on the basis of **pharmacokinetic data without** an additional clinical efficacy trial.

Guidance for Industry “Providing Clinical Evidence of Effectiveness for Human Drugs and Biological Products”, May 1998



CLINICAL PHARMACOLOGY & THERAPEUTICS

VOLUME 73 NUMBER 6

JUNE 2003

COMMENTARY


Hypothesis: A single clinical trial plus causal evidence of effectiveness is sufficient for drug approval

Carl C. Peck, MD, Donald B. Rubin, PhD, and Lewis B. Sheiner, MD *Washington, DC, Cambridge, Mass, and San Francisco, Calif*

When does FDA get involved ?

- **Preclinical (on request) phase**
 - IND requirements for CMC, animal testing, design of Phase 1 clinical studies
- **IND phase**
 - Type A, B, C meetings
- **NDA review phase**
 - Meetings + many communications
- **Marketing phase**
 - ADR surveillance
 - new uses, product changes, withdrawals

Figure 7: Industry - FDA Interactions During Drug Development



FDA Initiative: Innovation vs Stagnation - Challenge & Opportunity on the Critical Path to New Medical Products, March 2004

Guidance for Industry End-of-Phase 2A Meetings

DRAFT GUIDANCE

**U.S. Department of Health and Human Services
Food and Drug Administration
Center for Drug Evaluation and Research (CDER)**

**September 2008
Procedural**



University of California
San Francisco

UCSF-CDDS 2009



End of Phase 2a Meetings

- **Purpose:** ↓ Late phase clinical trial (2b, 3) unnecessary failure
- **Format:** non-binding scientific interchange.
- **Deliverables:**
 - Perform modeling (relevant phase 1/2a data) & simulation of next trial design employing
 - Mechanistic or empirical drug-disease model
 - Placebo effect (magnitude & time-course)
 - Rates for dropout and compliance. (prior FDA experience)
 - Recommendation on sponsors trial design + alternative including patient selection, dosage regimen,...
 - Answers to other questions from the clinical and clinical pharmacology development plan
- **Time-course:** ~ 6 weeks
- **Key sponsor & FDA participants:** physician, biostatistician, clinical pharmacology (pharmacometrics), project management

Adapted from R. Powell, FDA



Impact of Pharmacometrics on Drug Approval and Labeling Decisions: A Survey of 42 New Drug Applications

Submitted: April 4, 2005; Accepted: April 29, 2005; Published: October 7, 2005

Venkatesh A. Bhattaram,¹ Brian P. Booth,¹ Roshni P. Ramchandani,¹ B. Nhi Beasley,¹ Yaning Wang,¹ Veneeta Tandon,¹ John Z. Duan,¹ Raman K. Baweja,¹ Patrick J. Marroum,¹ Ramana S. Uppoor,¹ Nam Atiqur Rahman,¹ Chandrahas G. Sahajwalla,¹ J. Robert Powell,¹ Mehul U. Mehta,¹ and Jogarao V. S. Gobburu¹

¹Food and Drug Administration, Rockville, MD 20852

The value of quantitative thinking in drug development and regulatory review is increasingly being appreciated. Modeling and simulation of data pertaining to pharmacokinetic, pharmacodynamic, and disease progression is often referred to as the pharmacometrics analyses. The objective of the current report is to assess the role of pharmacometrics at the US Food and Drug Administration (FDA) in making drug approval and labeling decisions. The New Drug Applications (NDAs) submitted between 2000 and 2004 to the Cardio-renal, Oncology, and Neuropharmacology drug products divisions were surveyed. For those NDA reviews that included a pharmacometrics consultation, the clinical pharmacology scientists ranked the impact on the regulatory decision(s). Of about a total of 244 NDAs, 42 included a pharmacometrics component. Review of NDAs involved independent, quantitative evaluation by FDA pharmacometricians, even when such analysis was not conducted by the sponsor. Pharmacometrics were pivotal in regulatory decision making in half of the 42 NDAs. Of the 14 reviews that were pivotal to approval related decisions, 5 identified the need for additional trials, whereas 6 reduced the burden of conducting additional trials. Collaboration among the FDA clinical pharmacology, medical, and statistical reviewers and effective communication with the sponsors was critical for the impact to occur. The survey and the case studies emphasize the need for early interaction between the FDA and sponsors to plan the development more efficiently by appreciating the regulatory expectations better.

Of about a total of 244 NDAs,
42 included a pharmacometrics component....

Pharmacometric analyses were pivotal in regulatory decision making in more than half of the 42 NDAs.

Of 14 reviews that were **pivotal to approval decisions**,
... **6 reduced the burden** of conducting additional trials.

AAPS Journal 2005;7 (3) Article 51 (www.aapsj.org)

Impact of Pharmacometric Reviews on New Drug Approval and Labeling Decisions—a Survey of 31 New Drug Applications Submitted Between 2005 and 2006

VA Bhattaram¹, C Bonapace¹, DM Chilukuri¹, JZ Duan¹, C Garnett¹, JVS Gobburu¹, SH Jang¹, L Kenna¹, LJ Lesko¹, R Madabushi¹, Y Men¹, JR Powell¹, W Qiu¹, RP Ramchandani¹, CW Tornoe¹, Y Wang¹ and JJ Zheng¹

Exploratory analyses of data pertaining to pharmacokinetic, pharmacodynamic, and disease progression are often referred to as the pharmacometrics (PM) analyses. The objective of the current report is to assess the role of PM, at the Food and Drug Administration (FDA), in drug approval and labeling decisions. We surveyed the impact of PM analyses on New Drug Applications (NDAs) reviewed over 15 months in 2005–2006. The survey focused on both the approval and labeling decisions through four perspectives: clinical pharmacology primary reviewer, their team leader, the clinical team member, and the PM reviewer. A total of 31 NDAs included a PM review component. Review of NDAs involved independent quantitative evaluation by FDA pharmacometricians. PM analyses were ranked as important in regulatory decision making in over 85% of the 31 NDAs. Case studies are presented to demonstrate the applications of PM analysis.

PM analyses were ranked as important in regulatory decision making in over 85% of the 31 NDAs.

FDA – what's new?

■ Leadership

- Commissioner Hemurg (**Eschenbach**), (**Crawford**), (**McClellan**), (**Henney**), (**Kessler**), (**Young**)
- CDER Director (Woodcock)

■ Safety

- Drug withdrawals (Vioxx et al, 04; Raptiva 4-8-09/
 - Safety Oversight Board (05)
- ***PDUFA renewal 2007 -- FDAAA***

■ Initiatives

- ***Pediatric Initiatives (USA & Europe)***
- ***Improving drug development***
 - FDA leadership to improve drug development (2003)
 - ***Critical Path Initiative (2004)***
 - ***End-of-Phase 2a (EOP2a) meeting (04)***
 - ***Model-based Drug Development (05)***
 - ***Critical Path Opportunities List (06)***

FDAAA

- **Motivated by prominent market W/D's due to unexpected lack of safety**
- **New Authorities**
 - ❑ Public listing of all clinical trials & results
 - ❑ Post-approval trials and surveillance
 - ❑ Safety labeling
 - ❑ REMS (Risk Evaluation & Mitigation Strategy)
 - ❑ Pre-approval of Direct to Consumer Ads
 - ❑ Penalties
 - ❑ Advisory Committees
 - Risk Communication
 - COI

Pediatric Initiatives in US and Europe

■ US

- Pediatric Exclusivity - 1997
- Pediatric Research Equity Act - 1998
- Best Pharmaceuticals for Children Act - 2002

■ Europe

- Better Medicines for Children - 2007
 - Pediatric Investigations Plans (PIPs)
 - Pediatric Marketing Use Authorization (PUMAs)

EMA, Workshop on Modelling in Paediatric Medicines
London, April 14-15, 2008

Modeling & simulation in pediatric drug development and regulation

Carl Peck, MD

UCSF Center for Drug Development Science
UC-Washington Center, Washington DC

Department of Biopharmaceutical Sciences
School of Pharmacy,
University of California San Francisco




University of California
San Francisco



Applied to pediatrics

- **Principle** - Pediatric effectiveness / safety are inferred via mapping D-E-R from adults to pediatrics
- **Learn-Confirm Cycle(s)**
 - Pediatric Dose-Exposure relationship
 - Pediatric Exposure-Response relationship
 - **Confirmatory clinical trial if substantiation is required**
- **Requires**
 - Knowledge in adults of POM, POC, D-E-R, Efficacy / Safety
 - *Pharmacometric “model-based” learning pediatric PK, and confirming D-E-R*
- Learning’s are used to inform pediatric labeling

Pediatric Study Decision Tree





<http://www.fda.gov/cder/guidance/5341fnl.pdf>

Example - Enbrel (etanercept)

- **Adult RA approved 1998 - 2x/wk dosing**
 - 3 RCT's
- **Juvenile RA approved 1999 - 2x/wk dosing**
 - Population PK + **randomized withdrawal clinical trial**
- **Adult RA 1/wk dosing approved 2003**
 - Population PK + **safety RCT**
- **Juvenile RA 1/wk dosing approved 2003**
 - Population PK + simulation
- **Adult ankylosing spondylitis, psoriatic arthritis also approved 2003 - M&S only**



Adult vs Juvenile RA Enbrel PK, 1X & 2X/wk



0.8 mg/kg Once Weekly
0.4 mg/kg Twice Weekly

Mean, Once Weekly
Mean, Twice Weekly

Innovation



Stagnation

**Challenge and Opportunity
on the Critical Path
to New Medical
Products**



U.S. Department of Health and Human Services
Food and Drug Administration

March 2004



University of California
San Francisco


UCSF-CDDS 2009



Stagnation



Innovation



CRITICAL PATH

Adapted from S. Buckman:
"Biomarkers 101", RAPS, 2006



Guiding Principles of Critical Path Initiative

- **Coordinate collaborative efforts**
- **“toolkits” for better product development**
- **Encourage academic interest**
- **Opportunities to share existing knowledge & databases**
- **Develop enabling standards**

Adapted from S. Murphy: “*FDA Update on Critical Path Initiative*”, RAPS 2006, & FDA Critical Path Initiative 2004





The Critical Path to New Medical Products

The Critical Path Initiative is FDA's effort to stimulate and facilitate a national effort to modernize the scientific process through which a potential human drug, biological product, or medical device is transformed from a discovery or "proof of concept" into a medical product. [More](#).

Background

- [Press Releases](#)
- [Speeches](#)
- [Testimony](#)
- [Presentations](#)
- [Frequently Asked Questions](#)
- [More](#)

Opportunities List

- [Report](#) [PDF 447 KB]
- [List](#) [PDF 486 KB]
- [Press Release](#)

Critical Path Report (March 2004)

Success Stories

- [Vaccine Manufacturing](#)
- [West Nile Virus](#)
- [Digital Mammography](#)

Conferences and Events

- [Rapid Diagnostics Development and Infectious Disease Treatment, Nov. 6-7, 2006](#)
- [AAMC-FDA Conference on Drug Development Science, Jan. 13-14, 2005](#)
- [Medical Imaging As A Drug Development Tool: An FDA/DIA Workshop Presentations](#)

What's New

- [Opportunities-Press Release](#)
- [Report](#)
- [Opportunities List](#)
- [Questions and Answers](#)
- [Critical Path Fact Sheet](#)
- [Predictive Safety Testing Consortium-Press Release](#)
- [Predictive Safety Testing Consortium-Fact Sheet](#)
- [Quotes](#)

Projects Underway

- [Voluntary Genomics Data Submissions](#)
- [Predictive Safety Testing Consortium-Fact Sheet](#)
- [Request for Application: Cardiovascular Drug Safety and Biomarker Research](#)

[Contact Us](#)

<http://www.fda.gov/oc/initiatives/criticalpath/>



Critical Path Opportunities List



U.S. Department of Health and Human Services
Food and Drug Administration
March 2006



Critical Path Initiative

Six Priority Public Health Challenges

- Biomarker development
- Streamlining clinical trials
- Bioinformatics
- Efficient, quality manufacturing
- antibiotics and countermeasures to combat emerging infections and bioterrorism
- Developing therapies for children and adolescents

TOPIC 1: BETTER EVALUATION TOOLS	1	- 25. Imaging Biomarkers in Neurocognitive Diseases.....	5
Biomarker Qualification and Standards.....	1	26. Imaging in Cancer.....	5
1. Biomarker Qualification.....	1	27. Imaging in Chronic Obstructive Pulmonary Disease.....	6
2. Standards for Microarray and Proteomics-Based Identification of Biomarkers.....	1	28. Noninvasive Therapeutic Monitoring.....	6
Qualifying Disease- and Disorder-Specific Biomarkers.....	2	29. Imaging Implanted Devices.....	6
Asthma.....	2	Improving Predictions of Human Response from Disease Models.....	6
3. Role of Beta Adrenergic Receptor Polymorphisms in Asthma Treatments.....	2	30. Improving Extrapolation from Animal Data to Human Experience.....	6
Pregnancy.....	2	31. Better Model of Wound Repair.....	6
4. Measures of Effectiveness of Fertility Treatments.....	2	32. Better Animal Disease and Tissue Injury Models.....	6
5. Markers of Effectiveness of Treatment for Pre-term Labor.....	2	33. Better Disease Models for Predicting Biological Product Toxicity.....	7
Cardiovascular Biomarkers.....	2		
6. Surrogate Outcomes for Cardiovascular Drug Eluting Stents.....	2		
7. Circulating Biomarkers in Cardiovascular Diseases.....	2		
Infectious Diseases.....	2		
8. Proving the Efficacy of Preventive Vaccines.....	2		
9. Markers of Disease Progression in Hepatitis C.....	3		
10. Testing New Therapies for HIV Infection.....	3		
Cancer.....	3		
11. Markers of Disease Progression in Prostate Cancer.....	3		
12. Drug Targets as Critical Path Tools: Cancer Therapies.....	3		
Neuropsychiatric Diseases.....	3		
13. Diagnostic Markers for Neuropsychiatric Conditions.....	3		
Presbyopia.....	4		
14. Clinically Relevant Measures for Efficacy of Accommodating Intraocular Lenses.....	4		
Autoimmune and Inflammatory Diseases.....	4		
15. Markers of Disease Activity in Systemic Lupus Erythematosus, Inflammatory Bowel Disease, and Related Diseases.....	4		
Safety Biomarkers.....	4		
16. Predicting Adverse Reactions to Vaccines.....	4		
17. Early Indicators of Effects of Immune Responses on the Safety of Cell and Tissue Products.....	4		
18. Predicting Cardiac Toxicity.....	4		
19. Gene Therapy.....	4		
20. Modernizing Predictive Toxicology.....	4		
Advancing the Use of New Imaging Techniques.....	5		
21. Performance Standards for Imaging Displays.....	5		
22. Using Medical Imaging as a Product Development Tool.....	5		
23. Imaging Biomarkers in Cardiovascular Disease.....	5		
24. Imaging Biomarkers in Arthritis.....	5		



TOPIC 2: STREAMLINING CLINICAL TRIALS.....	8
Advancing Innovative Trial Designs	8
34. Design of Active Controlled Trials.....	8
35. Enrichment Designs.....	8
36. Use of Prior Experience or Accumulated Information in Trial Design	8
37. Development of Best Practices for Handling Missing Data	9
38. Development of Trial Protocols for Specific Therapeutic Areas.....	9
39. Analysis of Multiple Endpoints	9
Improving Measurement of Patient Responses.....	10
40. Measuring Disease-Related Symptoms	10
41. Measuring Patient-Centered Endpoints	10
42. New Trial Design in Oncology.....	10
43. Improving Efficacy Endpoints for Infectious Diseases	10
Streamlining the Clinical Trial Process	10
44. Development of Data Standards	10
45. Consensus on Standards for Case Report Forms	11
TOPIC 3: HARNESSING BIOINFORMATICS	12
46. Identification and Qualification of Safety Biomarkers	12
47. Virtual Control Groups in Clinical Trials	12
48. Adverse Event Data Mining	12
49. Multiple Complex Therapies	12
50. Modeling Device Performance	12
51. Clinical Trial Simulation	12
52. Failure Analysis.....	13
53. Natural History Databases for Rare Diseases.....	13





Key FDA Critical Path Activities Under Way in 2007

U.S. Department of Health and Human Services Food and Drug Administration June 2008

In March 2006, FDA published the second of two reports on the Critical Path to medical product development, *Critical Path Opportunities Report and List*. The *Opportunities Report and List* presented 78 specific scientific opportunities that, if undertaken, would help modernize the Critical Path sciences. The opportunities were identified through extensive outreach with patient groups, the pharmaceutical industry, academia, other federal agencies, and other health related organizations.

FDA also promised in that report to announce the specific activities it was undertaking in support of its Critical Path Initiative. As promised, the following pages list more than 40 Critical Path collaborations and research activities that currently are underway with FDA participation. The activities are organized according to the priority topics discussed in the *Opportunities Report and List*, also available on the Critical Path Web page. [1](#) Where appropriate, an activity is designated as directly linked to one of the 78 specific scientific opportunities, [2](#) or priority topics, in the *Opportunities Report and List*. The priority topics include the following:

- Better Evaluation Tools
- Streamlining Clinical Trials
- Harnessing Bioinformatics
- Moving Manufacturing into the 21st Century
- Developing Products to Address Urgent Public Health Needs
- Specific At-Risk Populations — Pediatrics

<http://www.fda.gov/oc/initiatives/criticalpath/opportunities06.html>

Public/Private Partnerships

- **Predictive Safety Testing Consortium**
 - CDER-OCP, CPath Institute, 15 pharma firms
 - Pre-clinical toxicogenomic biomarkers
 - Nephrotoxic biomarkers report expected 09
- **Biomarker Consortium**
 - NIH/ PhRMA/ FDA/CMS
 - regulatory pathway for biomarker validation
 - FDG-PET in NHL
- **Oncology Biomarker Qualification Initiative**
 - FDA, NCI and CMS
- **Microarray Quality Consortium**
- **Duke/FDA ECG & Clinical Trial Transformation Collaborations**

Some Final Observations

- **FDA regulation is science-based**
 - Advances innovation
 - Facilitates needed drugs for patients
- **FDA clinical guidances are increasingly based on principles of clinical pharmacology**
- **Social value: “guidance” versus “regulation”**
- **FDA guidance**
 - national “treasure” versus “national nuisance”
 - a bargain !

End of Presentation

